London Co. of Virginia Trims Stock Position in Enovis Corporation $ENOV

London Co. of Virginia lowered its holdings in shares of Enovis Corporation (NYSE:ENOV) by 18.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 371,972 shares of the company’s stock after selling 85,864 shares during the quarter. London Co. of Virginia’s holdings in Enovis were worth $9,909,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ENOV. Rubric Capital Management LP purchased a new stake in shares of Enovis during the 3rd quarter valued at about $83,435,000. AQR Capital Management LLC increased its position in shares of Enovis by 682.6% during the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares during the last quarter. Paradigm Capital Management Inc. NY increased its position in shares of Enovis by 41.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock valued at $34,913,000 after purchasing an additional 326,900 shares during the last quarter. ExodusPoint Capital Management LP increased its position in shares of Enovis by 163.4% during the 4th quarter. ExodusPoint Capital Management LP now owns 508,971 shares of the company’s stock valued at $13,559,000 after purchasing an additional 315,711 shares during the last quarter. Finally, Soleus Capital Management L.P. bought a new position in shares of Enovis during the 2nd quarter valued at approximately $9,878,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Up 2.8%

ENOV stock opened at $21.56 on Wednesday. Enovis Corporation has a 1-year low of $20.55 and a 1-year high of $36.82. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -1.08 and a beta of 1.38. The business has a 50 day simple moving average of $23.97 and a two-hundred day simple moving average of $24.44.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same period in the prior year, the company posted $0.81 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ENOV shares. BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Enovis in a research note on Friday, May 22nd. Evercore reiterated an “outperform” rating and set a $36.00 price objective on shares of Enovis in a research note on Friday, May 8th. Needham & Company LLC boosted their price objective on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Zacks Research downgraded Enovis from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 1st. Finally, Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $44.50.

Insider Activity at Enovis

In other news, insider Oliver Engert bought 1,200 shares of the stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider owned 51,840 shares of the company’s stock, valued at $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders purchased 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by corporate insiders.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.